vs
Side-by-side financial comparison of AECOM (ACM) and Bausch Health Companies Inc. (BHC). Click either name above to swap in a different company.
AECOM is the larger business by last-quarter revenue ($3.8B vs $2.8B, roughly 1.4× Bausch Health Companies Inc.). AECOM runs the higher net margin — 1.9% vs -3.7%, a 5.6% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 1.6%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $41.9M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -1.4%).
AECOM is an American multinational infrastructure consulting firm headquartered in Dallas, Texas.
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
ACM vs BHC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.8B | $2.8B |
| Net Profit | $74.5M | $-103.0M |
| Gross Margin | 7.3% | — |
| Operating Margin | 5.8% | 17.0% |
| Net Margin | 1.9% | -3.7% |
| Revenue YoY | 1.6% | 9.3% |
| Net Profit YoY | -48.0% | -205.1% |
| EPS (diluted) | $0.56 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.8B | — | ||
| Q4 25 | — | $2.8B | ||
| Q3 25 | $4.2B | $2.7B | ||
| Q2 25 | $4.2B | $2.5B | ||
| Q1 25 | $3.8B | $2.3B | ||
| Q4 24 | $4.0B | $2.6B | ||
| Q3 24 | $4.1B | $2.5B | ||
| Q2 24 | $4.2B | $2.4B |
| Q1 26 | $74.5M | — | ||
| Q4 25 | — | $-103.0M | ||
| Q3 25 | $120.4M | $179.0M | ||
| Q2 25 | $131.0M | $148.0M | ||
| Q1 25 | $143.4M | $-58.0M | ||
| Q4 24 | $167.0M | $98.0M | ||
| Q3 24 | $172.5M | $-85.0M | ||
| Q2 24 | $134.3M | $10.0M |
| Q1 26 | 7.3% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 7.9% | — | ||
| Q2 25 | 7.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 6.9% | — |
| Q1 26 | 5.8% | — | ||
| Q4 25 | — | 17.0% | ||
| Q3 25 | 5.7% | 23.1% | ||
| Q2 25 | 7.0% | 17.5% | ||
| Q1 25 | 6.8% | 12.2% | ||
| Q4 24 | 5.9% | 21.8% | ||
| Q3 24 | 5.8% | 12.7% | ||
| Q2 24 | 5.5% | 16.2% |
| Q1 26 | 1.9% | — | ||
| Q4 25 | — | -3.7% | ||
| Q3 25 | 2.9% | 6.7% | ||
| Q2 25 | 3.1% | 5.8% | ||
| Q1 25 | 3.8% | -2.6% | ||
| Q4 24 | 4.2% | 3.8% | ||
| Q3 24 | 4.2% | -3.4% | ||
| Q2 24 | 3.2% | 0.4% |
| Q1 26 | $0.56 | — | ||
| Q4 25 | — | $-0.30 | ||
| Q3 25 | $0.90 | $0.48 | ||
| Q2 25 | $0.98 | $0.40 | ||
| Q1 25 | $1.08 | $-0.16 | ||
| Q4 24 | $1.25 | $0.24 | ||
| Q3 24 | $1.27 | $-0.23 | ||
| Q2 24 | $0.98 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $1.3B |
| Total DebtLower is stronger | $2.6B | $20.8B |
| Stockholders' EquityBook value | $2.2B | $-554.0M |
| Total Assets | $11.9B | $26.4B |
| Debt / EquityLower = less leverage | 1.18× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.2B | — | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | $1.6B | $1.3B | ||
| Q2 25 | $1.8B | $1.7B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.6B | $719.0M | ||
| Q2 24 | $1.6B | $595.0M |
| Q1 26 | $2.6B | — | ||
| Q4 25 | — | $20.8B | ||
| Q3 25 | $2.6B | $21.0B | ||
| Q2 25 | $2.5B | $21.7B | ||
| Q1 25 | $2.5B | $21.5B | ||
| Q4 24 | $2.5B | $21.6B | ||
| Q3 24 | $2.5B | $21.5B | ||
| Q2 24 | $2.5B | $21.7B |
| Q1 26 | $2.2B | — | ||
| Q4 25 | — | $-554.0M | ||
| Q3 25 | $2.5B | $-565.0M | ||
| Q2 25 | $2.5B | $-764.0M | ||
| Q1 25 | $2.3B | $-1.2B | ||
| Q4 24 | $2.2B | $-1.3B | ||
| Q3 24 | $2.2B | $-1.2B | ||
| Q2 24 | $2.3B | $-1.2B |
| Q1 26 | $11.9B | — | ||
| Q4 25 | — | $26.4B | ||
| Q3 25 | $12.2B | $26.8B | ||
| Q2 25 | $12.3B | $27.3B | ||
| Q1 25 | $11.8B | $26.4B | ||
| Q4 24 | $11.8B | $26.5B | ||
| Q3 24 | $12.1B | $26.5B | ||
| Q2 24 | $12.0B | $26.5B |
| Q1 26 | 1.18× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.06× | — | ||
| Q2 25 | 0.99× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.11× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.07× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $70.2M | $495.0M |
| Free Cash FlowOCF − Capex | $41.9M | $403.0M |
| FCF MarginFCF / Revenue | 1.1% | 14.4% |
| Capex IntensityCapex / Revenue | 0.7% | 3.3% |
| Cash ConversionOCF / Net Profit | 0.94× | — |
| TTM Free Cash FlowTrailing 4 quarters | $616.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $70.2M | — | ||
| Q4 25 | — | $495.0M | ||
| Q3 25 | $196.1M | $405.0M | ||
| Q2 25 | $283.7M | $289.0M | ||
| Q1 25 | $190.7M | $211.0M | ||
| Q4 24 | $151.1M | $601.0M | ||
| Q3 24 | $298.8M | $405.0M | ||
| Q2 24 | $291.3M | $380.0M |
| Q1 26 | $41.9M | — | ||
| Q4 25 | — | $403.0M | ||
| Q3 25 | $134.1M | $314.0M | ||
| Q2 25 | $261.7M | $190.0M | ||
| Q1 25 | $178.3M | $96.0M | ||
| Q4 24 | $110.9M | $495.0M | ||
| Q3 24 | $274.5M | $334.0M | ||
| Q2 24 | $272.8M | $302.0M |
| Q1 26 | 1.1% | — | ||
| Q4 25 | — | 14.4% | ||
| Q3 25 | 3.2% | 11.7% | ||
| Q2 25 | 6.3% | 7.5% | ||
| Q1 25 | 4.7% | 4.2% | ||
| Q4 24 | 2.8% | 19.3% | ||
| Q3 24 | 6.7% | 13.3% | ||
| Q2 24 | 6.6% | 12.6% |
| Q1 26 | 0.7% | — | ||
| Q4 25 | — | 3.3% | ||
| Q3 25 | 1.5% | 3.4% | ||
| Q2 25 | 0.5% | 3.9% | ||
| Q1 25 | 0.3% | 5.1% | ||
| Q4 24 | 1.0% | 4.1% | ||
| Q3 24 | 0.6% | 2.8% | ||
| Q2 24 | 0.4% | 3.2% |
| Q1 26 | 0.94× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.63× | 2.26× | ||
| Q2 25 | 2.17× | 1.95× | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | 0.90× | 6.13× | ||
| Q3 24 | 1.73× | — | ||
| Q2 24 | 2.17× | 38.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACM
Segment breakdown not available.
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
